Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NXTC with free AI briefings, catalyst countdowns, and dilution alerts.

NXTC · NextCure, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.7M Cash on Hand
2.4mo Cash Runway
Follow NXTC by email Get an email when NXTC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NXTC, unsubscribe in one click. Privacy

📣 What NXTC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-B7-H4 Monoclonal Antibody NC762 Advanced or Metastatic Solid Tumors Phase 1/2 · NCT04875806 Terminated
LAIR-2 Fusion Protein NC410 Pancreatic Cancer Phase 2 · NCT06941857 Recruiting
Anti-S15 Monoclonal Antibody NC318 Advanced Non-small Cell Lung Cancer Phase 2 · NCT04699123 Active not recruiting
Nab-paclitaxel Advanced or Metastatic Solid Tumors Phase 1/2 · NCT04430933 Withdrawn
Irinotecan Pancreatic Cancer Phase 2 · NCT06941857 Recruiting
Fluorouracil Pancreatic Cancer Phase 2 · NCT06941857 Recruiting
Anti-LAIR1 Monoclonal Antibody NC525 Relapsed or Refractory Acute Myeloid Leukemia Phase 1 · NCT05787496 Terminated
Anti-CDH6 Antibody-drug Conjugate SIM0505 Advanced Solid Tumors Phase 1 · NCT06792552 Recruiting

Also used in these trials (approved or third-party drugs, not NXTC's own candidates): Docetaxel Anhydrous, Pemetrexed Disodium, Pembrolizumab, Oxaliplatin, Nivolumab, Ipilimumab, Leucovorin Calcium.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NXTC holds $8.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.9M/quarter from operations, an estimated runway of 2.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NXTC files for a raise →

👥 Who Owns NXTC

Insiders 23.1% Other 5%+ holders 4.9% Institutions (38 holders) 54.4% Public and other holders 17.6%
HolderTypeShares% of sharesAs of
ADAR1 Capital Management, LLC
10% owner
Insider 750,289 16.39% 2026-11-11
Ikarian Capital, LLC Institution (13G, 5%+) 500,282 10.93% 2026-09-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 475,626 10.39% 2026-09-30
JP Sailing Capital Ltd Institution (13G, 5%+) 455,001 9.94% 2026-09-30
Simcere Zaiming, Inc.
Former 10% Owner
Insider 308,636 6.74% 2026-08-10
Adage Capital Management, L.P. Institution (13G, 5%+) 277,202 6.05% 2026-06-30
Sofinnova Venture Partners IX, L.P. ("SV 5%+ holder (13D) 222,654 4.86% 2025-12-19

Share count 4,579,023 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NXTC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NXTC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.